Lkit Therapeutics: Exploiting Synethtic Lethality to Target p53 Mutant Cancers Using First-In-Class Potent and Selective Small Molecule Inhibitors of Lipid Kinases PI5P4Kα/β.
Maegi Medicine: First-in-class Immune Gene Therapy for Human Health
Athena Therapeutics
Overcoming PARP Inhibitor Resistance in Cancers
Apeiros Bioscience: Targeting Cancer with a Novel Antibody Drug Conjugate
